{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:07:25Z","timestamp":1789016845561,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rademikibart, an IL\u20104R\u03b1\u2010targeting antibody, demonstrated efficacy in a Phase 2b trial of adults with moderate\u2010to\u2010severe uncontrolled asthma (NCT04773678). We report exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count (EOS) and fractional exhaled nitric oxide (FeNO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients were randomized, double\u2010blind, to rademikibart 150\u2009mg or 300\u2009mg Q2W (600\u2010mg loading) or placebo, with medium\u2010to\u2010high dose inhaled corticosteroids and \u2265\u20091 reliever\/controller. Up to eight EOS\/FeNO subgroups were investigated, focusing on the following five: \u2265\u2009300\u2009cells\/\u03bcL and \u2265\u200925\u2009ppb (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200980); \u2265\u200925\u2009ppb (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009142); \u2265\u2009300\u2009cells\/\u03bcL (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009129); \u2265\u2009150\u2009cells\/\u03bcL (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009247); 150\u2013 &lt;\u2009300\u2009cells\/\u03bcL (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009118).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Prebronchodilator FEV\n                      <jats:sub>1<\/jats:sub>\n                      increased significantly at first assessment (Week 1) and was sustained throughout the 24\u2010week treatment period. FEV\n                      <jats:sub>1<\/jats:sub>\n                      and asthma control (ACQ\u20106) improvements were greatest when baseline EOS and FeNO were both elevated. At Week 1, after a 600\u2010mg loading dose, placebo\u2010adjusted FEV\n                      <jats:sub>1<\/jats:sub>\n                      increased by 422\u2009mL (\u2265\u2009300\u2009cells\/\u03bcL and \u2265\u200925\u2009ppb), 339\u2009mL (\u2265\u200925\u2009ppb), 324\u2009mL (\u2265\u2009300\u2009cells\/\u03bcL), 227\u2009mL (\u2265\u2009150\u2009cells\/\u03bcL), and 141\u2009mL (150\u2013 &lt;\u2009300\u2009cells\/\u03bcL). At Week 24, with 300\u2009mg Q2W, placebo\u2010adjusted FEV\n                      <jats:sub>1<\/jats:sub>\n                      increased by 519\u2009mL (\u2265\u2009300\u2009cells\/\u03bcL and \u2265\u200925\u2009ppb), 401\u2009mL (\u2265\u200925\u2009ppb), 394\u2009mL (\u2265\u2009300\u2009cells\/\u03bcL), 287\u2009mL (\u2265\u2009150\u2009cells\/\u03bcL), and 159\u2009mL (150\u2013 &lt;\u2009300\u2009cells\/\u03bcL). Exacerbations decreased by \u2265\u200963% per subgroup. Rademikibart was well tolerated. No eosinophilia (Preferred Term) was reported. Grade 1 eosinophil count increased did not lead to treatment discontinuation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rapid and sustained improvements were more pronounced in patients with type 2\u2010high biomarkers than previously reported in the overall study population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.70506","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:12:45Z","timestamp":1789013565000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase\n                    <scp>2b<\/scp>\n                    Randomized Clinical Trial"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2946","authenticated-orcid":false,"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine National Jewish Health  Denver Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-7520","authenticated-orcid":false,"given":"Praveen","family":"Akuthota","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine University of California San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9803-2321","authenticated-orcid":false,"given":"Barry","family":"Quart","sequence":"additional","affiliation":[{"name":"Connect Biopharma LLC  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-7443","authenticated-orcid":false,"given":"Ra\u00fal","family":"Collazo","sequence":"additional","affiliation":[{"name":"Connect Biopharma LLC  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"U.S. Centers for Disease Control and Prevention \u201cAsthma Data Visualization \u201dupdated January 4 2023 https:\/\/www.cdc.gov\/asthma\/data\u2010visualizations\/default.htm."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.22.1010"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/25310429.2025.2466920"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.04052"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.04.013"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41533\u2010024\u201000402\u2010w"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41533\u2010017\u20100014\u20101"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41533\u2010023\u201000336\u20109"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.7.825"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201901\u20100016OC"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106670"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00900\u20102019"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111684"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.051"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199810223391703"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02536\u20102017"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13403"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20102600(21)00124\u20107"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13081428"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.018"},{"key":"e_1_2_9_22_1","unstructured":"Global Initiative for Asthma \u201cGlobal Strategy for Asthma Management and Prevention \u201dhttps:\/\/ginasthma.org\/2025\u2010gina\u2010strategy\u2010report\/."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2018.1502301"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201039311\u20102"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.924"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202409\u20101708OC"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13656"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5041","volume-title":"Rapid Improvement in Lung Function Observed With Rademikibart in Patients With Moderate\u2010To\u2010Severe Uncontrolled Asthma","author":"Collazo R.","year":"2025"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.10.008"},{"issue":"6","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1742-1241.2002.tb11292.x","article-title":"Budesonide\/Formoterol (Symbicort) is Well Tolerated and Effective in Patients With Moderate Persistent Asthma","volume":"56","author":"Rosenhall L.","year":"2002","journal-title":"International Journal of Clinical Practice"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1397"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.1574"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(16)30307\u20105"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2026.04.019"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.05.019"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041031"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20102600(17)30125\u2010x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20102600(15)00042\u20109"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(16)31324\u20101"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.70506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.70506","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.70506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:12:48Z","timestamp":1789013568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.70506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":42,"alternative-id":["10.1111\/all.70506"],"URL":"https:\/\/doi.org\/10.1111\/all.70506","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"2026-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"all.70506"}}